Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. freshman Avg
|
New words:
Analyst, anticipated, attestation, Biolog, CA, Christopher, collectively, compensatory, correction, discontinued, disinterested, Document, Element, Enterprise, entirety, expressly, Flagship, Forward, Hayward, indpenednt, Inline, IPS, LabCorp, left, length, Linkbase, LP, made, McCarthy, Mountain, multiple, negotiation, pre, recovery, relevant, Schuster, Simon, Taxonomy, UK, XBRL
Removed:
evaluation, external, mitigate, occurred, result
Filing tables
Filing exhibits
IDXG similar filings
Filing view
External links
Exhibit 31.4
CERTIFICATION PURSUANT TO SECTION 302
OF THE SARBANES-OXLEY ACT OF 2002
I, Christopher McCarthy, certify that:
1. | I have reviewed this Annual Report on Form 10-K/A for the year ended December 31, 2022 of Interpace Biosciences, Inc. (the “registrant”); and | |
2. | Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report. |
Date: April 28, 2023 | /s/ Christopher McCarthy |
(Principal Financial Officer) |